JP4805848B2 - 腫瘍抗原の生物活性を特異的に阻止するモノクローナル抗体 - Google Patents

腫瘍抗原の生物活性を特異的に阻止するモノクローナル抗体 Download PDF

Info

Publication number
JP4805848B2
JP4805848B2 JP2006553229A JP2006553229A JP4805848B2 JP 4805848 B2 JP4805848 B2 JP 4805848B2 JP 2006553229 A JP2006553229 A JP 2006553229A JP 2006553229 A JP2006553229 A JP 2006553229A JP 4805848 B2 JP4805848 B2 JP 4805848B2
Authority
JP
Japan
Prior art keywords
antibody
cells
antibodies
cell
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2006553229A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008500025A (ja
JP2008500025A5 (enExample
Inventor
グラッソ、ルイジ
ニコライデス、ニコラス、シー．
サス、フィリップ、エム．
Original Assignee
モルフォテック、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モルフォテック、インク． filed Critical モルフォテック、インク．
Publication of JP2008500025A publication Critical patent/JP2008500025A/ja
Publication of JP2008500025A5 publication Critical patent/JP2008500025A5/ja
Application granted granted Critical
Publication of JP4805848B2 publication Critical patent/JP4805848B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2006553229A 2004-02-12 2005-02-11 腫瘍抗原の生物活性を特異的に阻止するモノクローナル抗体 Expired - Lifetime JP4805848B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54436404P 2004-02-12 2004-02-12
US60/544,364 2004-02-12
PCT/US2005/004240 WO2005080431A2 (en) 2004-02-12 2005-02-11 Monoclonal antibodies that specifically bind to folate receptor alpha

Publications (3)

Publication Number Publication Date
JP2008500025A JP2008500025A (ja) 2008-01-10
JP2008500025A5 JP2008500025A5 (enExample) 2011-08-18
JP4805848B2 true JP4805848B2 (ja) 2011-11-02

Family

ID=34886025

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006553229A Expired - Lifetime JP4805848B2 (ja) 2004-02-12 2005-02-11 腫瘍抗原の生物活性を特異的に阻止するモノクローナル抗体

Country Status (6)

Country Link
US (4) US20050232919A1 (enExample)
EP (3) EP1716179A2 (enExample)
JP (1) JP4805848B2 (enExample)
AU (1) AU2005214331B2 (enExample)
CA (1) CA2556027C (enExample)
WO (1) WO2005080431A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522196B2 (en) 2012-12-25 2016-12-20 Kagoshima University Antibody recognizing folate receptors α and β

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007537709A (ja) * 2003-05-23 2007-12-27 モーフオテク・インコーポレーテツド 腫瘍抗原を特異的に結合するモノクローナル抗体
AU2004261229A1 (en) * 2003-07-29 2005-02-10 Eisai, Inc. Antibodies and methods for generating genetically altered antibodies with enhanced effector function
WO2005080431A2 (en) 2004-02-12 2005-09-01 Morphotek, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
JP2009521206A (ja) 2005-04-22 2009-06-04 モルフォテック、インク． 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体
EP1900752A1 (en) 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
BRPI0807952A2 (pt) 2007-02-20 2014-06-10 Anaptysbio Inc Sistemas de hipermutação somática
AU2014203172B2 (en) * 2010-02-24 2016-03-10 Immunogen, Inc. Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof
SMT201700139T1 (it) * 2010-02-24 2017-05-08 Immunogen Inc Immunoconiugati contro il recettore 1 del folato e relativi usi
WO2011108502A1 (ja) 2010-03-02 2011-09-09 協和発酵キリン株式会社 改変抗体組成物
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS63430B1 (sr) 2010-10-01 2022-08-31 Modernatx Inc Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene
EP2629798A4 (en) * 2010-10-20 2014-05-28 Morphotek Inc GLYCOFORMS OF ANTI-RECEPTOR ANTIBODY-ALPHA FOLATE (ANTI-FRA)
JP6224456B2 (ja) 2010-11-05 2017-11-01 モルフォテック、インク． 葉酸受容体アルファ発現癌の診断および予後マーカーとしての葉酸受容体アルファ
CA3179835A1 (en) * 2011-01-18 2012-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
JP5881085B2 (ja) 2011-03-18 2016-03-09 国立大学法人 鹿児島大学 膵臓癌の治療用及び診断用の組成物
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
CN114441757A (zh) * 2011-04-01 2022-05-06 伊缪诺金公司 用于增加folr1癌症治疗的功效的方法
CN107903325B (zh) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
JP6220333B2 (ja) 2011-07-15 2017-10-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗葉酸受容体アルファ抗体およびその使用
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3682905T3 (da) 2011-10-03 2022-02-28 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
DE12858350T1 (de) 2011-12-16 2021-10-07 Modernatx, Inc. Modifizierte mrna zusammensetzungen
US9629918B2 (en) 2012-02-29 2017-04-25 Purdue Research Foundation Folate receptor alpha binding ligands
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
HK1206601A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP6122948B2 (ja) * 2012-05-15 2017-04-26 モルフォテック， インコーポレイテッド 胃癌の治療のための方法
MX362514B (es) 2012-08-31 2019-01-22 Immunogen Inc Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato.
WO2014055771A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
EP2930240B1 (en) 2012-12-07 2018-08-01 Kyowa Hakko Kirin Co., Ltd. Anti-folr1 antibody
MX379355B (es) 2012-12-21 2025-03-11 Altrubio Inc Enlazadores autodestructivos hidrofilos y conjugados de los mismos.
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
KR20240068778A (ko) * 2013-05-14 2024-05-17 이뮤노젠 아이엔씨 항-folr1 면역접합체 투약 섭생
WO2014205342A2 (en) 2013-06-20 2014-12-24 Morphotek, Inc. Methods for treatment of ovarian cancer
SG11201601037YA (en) 2013-08-30 2016-03-30 Immunogen Inc Antibodies and assays for detection of folate receptor 1
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015186823A1 (ja) * 2014-06-06 2015-12-10 協和発酵キリン株式会社 Ｆｏｌｒ１標的薬および葉酸代謝拮抗剤によるがん患者のための治療方法並びに医薬
SG11201610620UA (en) * 2014-06-20 2017-01-27 Bioalliance Cv Anti-folate receptor aplha (fra) antibody-drug conjugates and methods of using thereof
DK4141032T3 (da) 2014-11-20 2024-08-05 Hoffmann La Roche Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler og PD-1-aksebindende antagonister
DK3221356T3 (da) 2014-11-20 2020-11-02 Hoffmann La Roche T-celleaktiverende, bispecifikke, antigenbindende molekyler mod folr1 og cd3
DK3221357T3 (da) 2014-11-20 2020-08-10 Hoffmann La Roche Fælles letkæder og fremgangsmåder til anvendelse
EP3034130B1 (en) 2014-12-19 2019-12-04 Althia Health, S.L. Monoclonal antibody for the diagnosis, treatment and/or prevention of brain tumors and brain lesions
SG11201708546UA (en) * 2015-04-17 2017-11-29 Morphotek Inc Methods for treating lung cancer
JP6880006B2 (ja) 2015-09-17 2021-06-02 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫複合体を含む治療組み合わせ
AU2017206074B2 (en) 2016-01-08 2023-09-07 Altrubio Inc. Tetravalent anti-PSGL-1 antibodies and uses thereof
PE20181953A1 (es) * 2016-03-02 2018-12-17 Eisai Randd Man Co Ltd Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
EP3496756A4 (en) 2016-08-12 2020-07-22 L.E.A.F Holdings Group LLC ALPHA AND GAMMA-D ANTIFOLATES OF POLYGLUTAMATES AND THEIR USES.
US10822410B2 (en) 2016-11-23 2020-11-03 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
JP7487107B2 (ja) 2018-02-07 2024-05-20 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化葉酸代謝拮抗薬およびその使用
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
EP3749317A4 (en) 2018-02-07 2022-06-22 L.E.A.F Holdings Group LLC PEMETREXED ALPHA-POLYGLUTAMATE AND ASSOCIATED USES
WO2019157145A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated pemetrexed and uses thereof
EP3749319A4 (en) 2018-02-07 2022-06-22 L.E.A.F Holdings Group LLC TETRAHYDROFOLATES ALPHA POLYGLUTAMATE AND THEIR USES
CN111954529A (zh) 2018-02-07 2020-11-17 L.E.A.F.控股集团公司 α聚谷氨酸化氨甲蝶呤及其用途
CA3090391A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated raltitrexed and uses thereof
US11730738B2 (en) 2018-02-07 2023-08-22 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
US12310966B2 (en) 2018-02-07 2025-05-27 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
CA3090943A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
WO2019160734A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
EP3752156A4 (en) 2018-02-14 2021-10-27 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMIZED PRALATREXATE AND USES THEREOF
EP3752155A4 (en) 2018-02-14 2022-03-16 L.E.A.F Holdings Group LLC GAMMA POLYGLUTAMATE METHOTREXATE AND USES THEREOF
EP3755335A4 (en) 2018-02-14 2022-06-22 L.E.A.F Holdings Group LLC GAMMA POLYGLUTAMIC TETRAHYDROFOLATES AND THEIR USES
WO2019177854A1 (en) * 2018-03-13 2019-09-19 Phanes Therapeutics, Inc. Anti-folate receptor 1 antibodies and uses thereof
KR102275930B1 (ko) 2018-03-14 2021-07-12 (주)알테오젠 Folr1에 특이적으로 결합하는 항체 및 그의 용도
US12172986B2 (en) 2018-06-01 2024-12-24 Eisai R&D Management Co., Ltd Splicing modulator antibody-drug conjugates and methods of use
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CA3114931A1 (en) 2018-12-13 2020-06-18 Eisai R&D Management Co., Ltd. Herboxidiene antibody-drug conjugates and methods of use
KR20220004687A (ko) 2019-04-29 2022-01-11 이뮤노젠 아이엔씨 이중파라토프 fr-알파 항체 및 면역접합체
CN111393528B (zh) * 2020-01-19 2023-01-31 中国药科大学 一种靶向叶酸受体α的单链抗体及其应用
WO2021207827A1 (en) * 2020-04-15 2021-10-21 Zymeworks Inc. Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof
CA3245732A1 (en) 2022-03-11 2023-09-14 Mablink Bioscience ANTIBODY-DRUG CONJUGATIONS AND THEIR USES
EP4342488A1 (en) 2022-09-26 2024-03-27 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor specific for folate receptor 1
CN118047871A (zh) * 2022-11-16 2024-05-17 迈威(上海)生物科技股份有限公司 一种靶向FRα的抗体或其抗原结合片段及其应用
CN116462768B (zh) * 2023-06-13 2023-09-22 浙江时迈药业有限公司 针对folr1的双特异性抗体及其用途
WO2025034965A1 (en) * 2023-08-09 2025-02-13 Board Of Regents, The University Of Texas System Targeted therapeutic delivery of lipid nanoparticles

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US4851332A (en) * 1985-04-01 1989-07-25 Sloan-Kettering Institute For Cancer Research Choriocarcinoma monoclonal antibodies and antibody panels
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5006470A (en) * 1987-04-16 1991-04-09 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies to cell surface antigens of melanoma
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5688488A (en) * 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992007081A2 (en) 1990-10-12 1992-04-30 THE UNITED STATES OF AMERICA as represented by TH E SECRETARY, U.S. DEPARTMENT OF COMMERCE A monoclonal antibody
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5646253A (en) * 1994-03-08 1997-07-08 Memorial Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
DE4335025A1 (de) * 1993-10-14 1995-04-20 Boehringer Ingelheim Int Endosomolytisch wirksame Partikel
US6191268B1 (en) * 1993-12-17 2001-02-20 Dana-Farber Cancer Institute Compositions and methods relating to DNA mismatch repair genes
AU697269B2 (en) * 1994-01-27 1998-10-01 Human Genome Sciences, Inc. Human DNA mismatch repair proteins
DE19513676A1 (de) * 1995-04-11 1996-10-17 Behringwerke Ag Cytoplasmatische Expression von Antikörpern, Antikörperfragmenten und Antikörperfragmentfusionsmolekülen in E.coli
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
CA2241604C (en) * 1996-01-05 2010-03-30 Ira Pastan Mesothelium antigen and methods and kits for targeting it
BR9708910A (pt) * 1996-05-04 1999-08-03 Zeneca Ltd Anticorpo conjugado sequência de polinucleotídeos vetor célula hospedeira hibridoma composição farmacêutica processos para fabricar um anticorpo ou um conjugado e para tratar um humano ou animal em necessidade deste tratamento
US6809184B1 (en) * 1997-12-01 2004-10-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
US6146894A (en) * 1998-04-14 2000-11-14 The Johns Hopkins University Method for generating hypermutable organisms
US6365410B1 (en) * 1999-05-19 2002-04-02 Genencor International, Inc. Directed evolution of microorganisms
MXPA01011950A (es) 1999-05-27 2002-05-06 Gov Health & Human Serv Inmunoconjugados que tienen alta afinidad de enlace.
DE60118370T2 (de) * 2000-06-05 2006-12-07 Corixa Corp., Seattle Leader-anteile zur erhöhung der sekretion von rekombinanten proteinen aus einer wirtzelle
US6808894B1 (en) 2000-11-07 2004-10-26 Morphotek, Inc. Methods for generating genetically altered antibody producing cell lines with improved antibody characteristics
DE60041665D1 (de) * 2000-11-07 2009-04-09 Morphotek Inc Ten antikörperproduzierenden zelllinien mit verbesserten antikörpereigenschaften
CA2434926C (en) 2001-01-15 2014-04-01 Morphotek, Inc. Chemical inhibitors of mismatch repair
US7110683B2 (en) * 2001-03-30 2006-09-19 Agere Systems Inc. Compensation of polarization mode dispersion in single mode fiber for maximum-likelihood sequence estimation
RU2316349C2 (ru) 2001-05-02 2008-02-10 Пердью Рисерч Фаундейшн Лечение и диагностика заболеваний, опосредованных макрофагами
EP1258255A1 (en) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
CN1541226A (zh) * 2001-05-18 2004-10-27 ���ָ��Ӣ��ķ�������Ϲ�˾ CD44v6特异性的抗体
CA2481334A1 (en) 2002-04-01 2003-10-16 Anthony C. Stevens Tissue-specific endothelial membrane proteins
GB0214013D0 (en) 2002-06-18 2002-07-31 Euro Celtique Sa Pharmaceutical product
WO2004009782A2 (en) * 2002-07-19 2004-01-29 Morphotek, Inc. Methods for generating enhanced antibody-producing cell lines with improved growth characteristics
JP2007537709A (ja) * 2003-05-23 2007-12-27 モーフオテク・インコーポレーテツド 腫瘍抗原を特異的に結合するモノクローナル抗体
AU2004261229A1 (en) * 2003-07-29 2005-02-10 Eisai, Inc. Antibodies and methods for generating genetically altered antibodies with enhanced effector function
WO2005014652A1 (en) 2003-08-05 2005-02-17 Morphotek, Inc. A variant cell surface molecule associated with cancer
WO2005080431A2 (en) 2004-02-12 2005-09-01 Morphotek, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
US20090285806A1 (en) * 2004-10-05 2009-11-19 Martin Sinacore Methods and compositions for improving recombinant protein production
ES2429340T3 (es) * 2005-03-10 2013-11-14 Morphotek, Inc. Anticuerpos anti-mesotelina
WO2006105141A1 (en) * 2005-03-30 2006-10-05 Purdue Research Foundation Method for cancer prognosis using cellular folate vitamin receptor quantification
JP2009521206A (ja) 2005-04-22 2009-06-04 モルフォテック、インク． 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体
US8795633B2 (en) * 2005-09-23 2014-08-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
US20080312093A1 (en) * 2005-11-04 2008-12-18 Johji Inazawa Method for detecting cancer and a method for suppressing cancer
EP1900752A1 (en) * 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
EP2087337A4 (en) * 2006-11-03 2010-09-08 Purdue Research Foundation METHOD AND DEVICE FOR EX-VIVO FLOW CYTOMETRY
US9138484B2 (en) 2007-06-25 2015-09-22 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US20090087849A1 (en) * 2007-09-06 2009-04-02 Tripath Imaging, Inc. Nucleic acid-based methods and compositions for the detection of ovarian cancer
GB0725077D0 (en) 2007-12-21 2008-01-30 Univ Murcia Antifolate com[ounds for the treatment of melanoma
WO2009132081A2 (en) 2008-04-24 2009-10-29 The Research Foundation Of State University Of New York Monoclonal antibody-based targeting of folate receptors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522196B2 (en) 2012-12-25 2016-12-20 Kagoshima University Antibody recognizing folate receptors α and β

Also Published As

Publication number Publication date
WO2005080431A2 (en) 2005-09-01
US9624297B2 (en) 2017-04-18
CA2556027C (en) 2015-11-24
US20170184603A1 (en) 2017-06-29
EP3101034A1 (en) 2016-12-07
AU2005214331A1 (en) 2005-09-01
WO2005080431A3 (en) 2005-11-24
JP2008500025A (ja) 2008-01-10
EP1716179A2 (en) 2006-11-02
US20090274697A1 (en) 2009-11-05
US9650440B2 (en) 2017-05-16
AU2005214331B2 (en) 2011-09-15
US10509037B2 (en) 2019-12-17
EP2316857A1 (en) 2011-05-04
CA2556027A1 (en) 2005-09-01
US20130189272A1 (en) 2013-07-25
US20050232919A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
JP4805848B2 (ja) 腫瘍抗原の生物活性を特異的に阻止するモノクローナル抗体
RU2770590C2 (ru) Антитела против pd-l1 и их варианты
US7592426B2 (en) Anti-mesothelin antibodies
JP5775458B2 (ja) 抗α２インテグリン抗体を使用する処置
JP7711079B2 (ja) Ｉｌ４ｒに結合する抗体とその使用
JP2009213486A (ja) インスリン様成長因子ｉ受容体に対する抗体及びその使用
JP2021507704A (ja) エフェクター機能を改良したヒトＩｇＧのＦｃ領域改変体
JP2012100676A (ja) 免疫エフェクター活性を有するエンドシアリン細胞に内部移行する抗体
CA2526647A1 (en) Anti alpha - folate - receptor - tetramer antibodies
US20120189620A1 (en) Methods for treating non-functioning pituitary adenoma
JP2025519056A (ja) Ｋｌｒｂ１結合剤及びその使用方法
WO2022166987A1 (zh) 结合lag-3的抗体及其用途
AU2017202341B2 (en) Monoclonal antibodies that specifically bind to folate receptor alpha
AU2013202884B2 (en) Monoclonal antibodies that specifically bind to folate receptor alpha
AU2011253933B2 (en) Monoclonal antibodies that specifically bind to folate receptor alpha
CN114364695A (zh) 特异性识别c5a的抗体及其应用
CN120569402A (zh) Klrb1结合剂及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080209

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20090609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110318

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110425

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110506

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20110510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110525

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110627

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110627

TRDD Decision of grant or rejection written
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110627

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110720

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110811

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4805848

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140819

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term